

## Publications

1. Saraf J, Kalia K, Bhattacharya P, **Tekade RK\***, Growing Synergy of Nanodiamonds in Neurodegenerative Interventions, *Drug Discovery Today*, 2019, 24, 584-594. Doi: 10.1016/j.drudis.2018.10.012 (IF: 6.36).
2. Pandey PK, Maheshwari R, Raval N, Gondaliya P, Kalia K, **Tekade RK\***. Nanogold-core multifunctional dendrimer for pulsatile chemo-, photothermal- and photodynamic- therapy of rheumatoid arthritis. *J Colloid Interface Sci.* 2019, 22, 544:61-77. Doi: 10.1016/j.jcis.2019.02.073 (IF: 5.1).
3. Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, **Tekade RK\***. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. *Mater Sci Eng C Mater Biol Appl.* 2019, 98, 1252-1276. Doi: 10.1016/j.msec.2019.01.066 (IF: 5.091).
4. Muniswamy JJ, Raval N, Kiran Kalia, **Tekade RK\***. 'Dendrimer-Cationized-Albumin' Encrusted polymeric nanoparticle Improves BBB Penetration and Anticancer Activity of Doxorubicin, *International J. Pharmaceutics*, 2019, 15, 77-99. doi: 10.1016/j.ijpharm.2018.11.035 (IF: 3.89).
5. Kuche M, Tambe V, Jogi H, Maheshwari R, Raval R, Kalia K, **Tekade RK\***. Carbon nanotubes based advanced dermal therapeutics: Current trends and future potential, *RSC-Nanoscale*, 2018,10, 8911-8937. DOI: 10.1039/c8nr01383g (IF: 7.36).
6. Ghanghoria R, Kesharwani P, **Tekade RK\***, Jain NK. Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers. *J. Controlled Release*, 2018, 10, 277-301. DOI: 10.1016/j.jconrel.2016.11.002 (IF-7.26).
7. Jogi H, Maheshwari R, Raval N, Kuche K, Tambe V, **Tekade RK\***. Carbon nanotubes in the delivery of anticancer herbal drugs, *Nanomedicine (London)* 2018, 15, 1187-1220. DOI: 10.2217/nnm-2017-0397 (IF: 4.81).
8. Mahajan S, Patharkar A, Kuche K, Maheshwari R, Deb PK, Kalia K, **Tekade RK**, Functionalized carbon nanotubes as emerging delivery system for the treatment of cancer, *International J. Pharmaceutics* 2018, 5, 540-558. DOI: 10.1016/j.ijpharm.2018.07.027 (IF- 3.89).
9. Sengupta P, Chatterjee B, **Tekade RK**. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. *International J. Pharmaceutics* 2018, 543, 328-344. DOI: 10.1016/j.ijpharm.2018.04.007 (IF: 3.69).
10. Kumavat A, Dapse P, Kumar N, Mishra D, Maheshwari R, Bhattacharya P, **Tekade RK\***, Budding alliance of Nanotechnology in RNA interference therapeutics, *Current Pharmaceutical Design*, 2018 [Ahead of print] DOI: 10.2174/1381612824666180807113948 (IF- 3.35).
11. Shah K, Chawla S, Agrawal A, Reddy G, Maheshwari R, Kalia K, **Tekade RK\***. Nanostructured Hyaluronic acid-based materials for the delivery of siRNA. *Current Pharmaceutical Design*, 2018 [Ahead of print]. DOI: 10.2174/1381612824666180807123705 (IF- 3.35).
12. Gorain B, Choudhury H, Pandey M, Kesharwani P, Abeer MM, **Tekade RK**, Carbon nanotube scaffolds as emerging nanoplatform for myocardial tissue regeneration: A review of recent developments and therapeutic implications. *Biomed Pharmacother.* 2018, 104, 496-508. DOI: 10.1016/j.biopha.2018.05.066 (IF: 2.83).
13. Lalu L, Tambe V, Pradhan D. **Tekade RK\***. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions. *J. Controlled Release*, 2017, 268, 19-39. DOI: 10.1016/j.jconrel.2017.07.035 (IF: 7.78).
14. **Tekade RK\***, Sun X. The Warburg effect and glucose-derived cancer theranostics. *Drug Discovery Today*, 2017, 22, 1637-1653. DOI: 10.1016/j.drudis.2017.08.003 (IF: 6.36).

15. Al-Qattan MN, Deb PK, **Tekade RK\***. Molecular dynamics simulation strategies for designing carbon-nanotube-based targeted drug delivery. *Drug Discovery Today*, 2017, 2, 235-250. DOI: 10.1016/j.drudis.2017.10.002 (IF: 6.36).
16. B. Gorain, M. Tekade, P. Kesharwani, A.K. Iyer, K. Kalia, **R.K. Tekade\***. The use of nanoscaffolds and dendrimers in tissue engineering, *Drug Discovery Today*, 2017, 22, 652-664. DOI: 10.1016/j.drudis.2016.12.007 (IF: 6.36).
17. Wickens JM, Alsaab HO, Kesharwani P, Bhise K, Amin MCIM, **Tekade RK**, et al. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. *Drug Discovery Today*, 2017, 22, 665-680. DOI: 10.1016/j.drudis.2016.12.009. (IF: 6.36).
18. Maheshwari R, Tekade M, Gondaliya P, Kalia K, D'Emanuele A, **Tekade RK\***. Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers. *Nanomedicine (London)*, 2017, 12, 2653-2675. DOI: 10.2217/nnm-2017-0210 (IF: 4.75).
19. Choudhury H, Gorain B, Pandey M, Kumbhar SA, **Tekade RK**, et al. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. *International J. Pharmaceutics* 2017, 30, 506-522. DOI: 10.1016/j.ijpharm.2017.07.018 (IF: 3.69).
20. V. Tambe, S. Thakkar, N. Raval, D. Sharma, K. Kalia, **R.K. Tekade\***. Surface Engineered Dendrimers in SiRNA Delivery and Gene Silencing, *Current pharmaceutical design*, 2017, 23, 2952-2975. DOI: 10.2174/1381612823666170314104619 (IF- 3.35).
21. N. Soni, M. Tekade, P. Kesharwani, P. Bhattacharya, R. Maheshwari, K. Dua, P.M. Hansbro, **R.K. Tekade\*** Recent Advances in Oncological Submissions of Dendrimer, *Current pharmaceutical design*, 2017, 23, 3084-3098. DOI: 10.2174/1381612823666170329150201 (IF- 3.35).
22. Choudhury H, Gorain B, Chatterjee B, Mandal UK, Sengupta P, **Tekade RK**. Pharmacokinetic and Pharmacodynamic Features of Nanoemulsion Following Oral, Intravenous, Topical and Nasal Route. *Current Pharmaceutical Design*, 2017, 23, 2504-2531. DOI: 10.2174/1381612822666161201143600 (IF- 3.35).
23. Dua K, Shukla SD, **Tekade RK**, Hansbro PM. Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases? *Drug delivery and Translational Research*, 2017, 7, 179-187. DOI: 10.1007/s13346-016-0349-0 (IF- 3.09).
24. Choudhury H, Gorain B, **Tekade RK**, et al. Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity. *Regulatory Toxicology and Pharmacology* (2017) 91, 179-189. doi: 10.1016/j.yrtph.2017.10.023 (IF-2.3).
25. Sarmah D, Saraf J, Kaur K, Pravalika K, **Tekade RK**, Borah A, Kalia K, Dave KR, Bhattacharya B. Stroke Management: An Emerging Role of Nanotechnology. *Micromachines*, 8, 2017, 262-275. DOI: 10.3390/mi8090262 (IF- 2.22).
26. Bhise K, Sau S, Alsaab H, Kashaw SK, **Tekade RK**, Iyer AK. Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship. *Therapeutics Delivery*, 2017, 8, 1003-1018. DOI: 10.4155/tde-2017-0062 (IF-1).
27. Dua K, Bebawy M, Awasthi R, **Tekade RK**, et al. Chitosan and Its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems. *Pharmaceutical Nanotechnology*, 2017, 5, 243-249). DOI: 10.2174/2211738505666170808095258 (IF- 1).
28. Rahul M, Piyooosh S, Tekade M, Atreriya U, Dua K, Hansbro PM, **Tekade RK\***. Microsponge embedded tablet for sustained delivery of nifedipine. *Pharmaceutical Nanotechnology* 2017, 5, 192-202. DOI: 10.2174/2211738505666170921125549. (IF-1).

29. **Tekade RK\***, Tekade M, Kesharwani P. RNAi combined Nano Chemotherapeutics to tackle Resistant Tumors, *Drug Discovery Today* 2016, 21, 1761-1774. DOI: 10.1016/j.drudis.2016.06.029. PMID: 27380716 (IF- 5.96).
30. Ghanghoria R, **Tekade RK\***, Mishra AK, Chuttani K, Jain NK. Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel. *Nanomedicine (Lond)*. 2016, 11, 797-816. DOI: 10.2217/nnm.16.19. PMID: 26980704 (IF- 5.4).
31. Soni N, Soni N, Pandey H, Maheshwari R, Kesharwani P, **Tekade RK\***. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. *J Colloid Interface Sci.* 2016, 481, 107-16. DOI: 10.1016/j.jcis.2016.07.020. PMID: 27459173 (IF- 3.782).
32. Moeendarbari S, **Tekade RK**, Mulgaonkar A, Christensen P, et al. Theranostic Nanoseeds for Efficacious Internal Radiation Therapy of Unresectable Solid Tumors. *Nature Scientific reports*, 2016, 6, 20614. DOI:10.1038/srep20614 (IF- 5.578).
33. Mansuri S, Kesharwani P, **Tekade RK\***, Jain NK. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. *European J. Pharm Biopharmaceutics* 2016 102:202-13 DOI: 10.1016/j.ejpb.2015.10.015. PMID: 26563727 (IF- 4.3).
34. Kesharwani P, Jain A, Jain A, Jain AK, Garg NK, **Tekade RK**, Thakur RRS, Iyer AK. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors. *RSC Advances*, 2016, 6, 89040-89050. DOI: 10.1039/C6RA17290C. (IF- 3.289).
35. Gorain B, Choudhury H, Tekade RK, Karan S, Jaisankar P, Pal TK. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. *Regul Toxicol Pharmacol.* 2016, 82:20-31. DOI: 10.1016/j.yrtph.2016.10.020 (IF-2.3).
36. Dwivedi N, Shah J, Mishra V, Mohd Amin MC, Iyer AK, **Tekade RK**, Kesharwani P. Dendrimer-mediated approaches for the treatment of brain tumor. *J Biomater Sci Polym Ed.* 2016, 27, 557-80. DOI: 10.1080/09205063.2015.1133155. PMID: 26928261 (IF- 1.68).
37. Mansuri S, Kesharwani P, Jain K, **Tekade RK**, Jain NK. Mucoadhesion: A promising approach in drug delivery system. *Reactive and Functional Polymers* 100, 151-172 DOI:10.1016/j.reactfunctpolym.2016.01.011. (IF- 2.725).
38. Gorain B, Choudhury H, **Tekade RK**, Karan S, Jaisankar P, Pal TK. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. *Regul Toxicol Pharmacol.* 2016, 1, 20-31. DOI: 10.1016/j.yrtph.2016.10.020. PMID: 27815174. (IF- 2.27).
39. Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, **Tekade RK\***. Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. *J. Biomedical Research* 2016, 30, 149–161. DOI: 10.7555/JBR.30.20150074. PMID: PMC4820892. (IF- 0.65).
40. **Tekade RK**, Tekade M, Dubey BK, Chauhan AS. Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of antitumor therapeutics, *Pharmaceutical Research* 2015, 32, 910-28. DOI: 10.1007/s11095-014-1506-0. PMID: 25205461 (IF- 3.95).
41. **Tekade RK**, Maheshwari RGS, Sharma PA, Tekade M, Chauhan AS. siRNA therapy, challenges and underlying perspectives of dendrimer as delivery vector. *Current Pharm. Design* 2015;21(31):4614-36, PMID: 26486147 (IF- 3.35).
42. **Tekade RK\***, Contemporary siRNA Therapeutics and current the-state-of-art. *Current Pharm. Design* 2015;21(31):4527-8. PMID: 26362643 (IF- 3.35).
43. Kesharwani P, **Tekade RK**, Jain NK. Formulation development and *in vitro-in vivo* assessment of 4.0g PPI dendrimer as cancer targeting vector. *Nanomedicine (London)* 2015; 32, 1438-50 DOI: 10.2217/nnm.13.210. PMID: 24593000 (IF- 5.82).

44. Kesharwani P, **Tekade RK**, Jain NK. Dendrimer generational nomenclature: the need to harmonize. *Drug Discov Today*. 2015, 20, 5, 497-499 DOI: 10.1016/j.biomaterials.2014.03.064. PMID: 24731713 (IF- 5.96).
45. Kesharwani P, **Tekade RK**, Jain NK. Generation dependent safety and efficacy of folic Acid conjugated dendrimer based anticancer drug formulations. *Pharmaceutical Research* 2015, 32(4):1438-50 DOI: 10.1007/s11095-014-1549-2. PMID: 25330744 (IF- 3.95).
46. Maheshwari RG, Thakur S, Singhal S, Patel RP, Tekade M, **Tekade RK\***. Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin. *Science of Advanced Materials*, 2015, 7, 1163-1176 DOI: <http://dx.doi.org/10.1166/sam.2015.2245> (IF- 2.9).
47. Sharma PA, Maheshwari RGS, Tekade M, **Tekade RK\***. Nanomaterial based approaches for the diagnosis and therapy of cardiovascular diseases. *Current Pharmaceutical Design* 2015;21(30):4465-78. PMID: 26354926 (Im5pact Factor- 3.35)
48. Maheshwari RGS, Tekade M, Sharma PA, **Tekade RK\***. Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders. *Current Pharmaceutical Design* 2015;21(30):4427-40. PMID: 26471319 (IF- 3.35).
49. Chopdey PK, **Tekade RK\***, Mehra NK, Mody N, Jain NK. An investigation on glycyrrhizin conjugated dendrimer and multi walled carbon nanotubes for liver specific delivery of doxorubicin. *J. Nanoscience and Nanotechnology*, 2015 15 (2), 1088-1100 PMID: 26353617 (IF-1.33).
50. Huang CW, Kearney V, Moeendarbari S, Jiang RQ, Christensen P, Tekade RK, Sun X, Mao WH, Hao YW. Hollow Gold Nanoparticles as Biocompatible Radiosensitizer: An *In Vitro* Proof of Concept Study, *Journal of Nano Research*, 2015, 32, 106-112. (IF- 2.11).
51. Kesharwani P, **Tekade RK**, Jain NK Generation dependent cancer targeting potential of poly (propyleneimine) dendrimer. *Biomaterials* 2014, 35, 5539-48. 2014 DOI: 10.1016/j.biomaterials.2014.03.064. PMID: 24731713 (IF- 8.3).
52. Gandhi NS, **Tekade RK**, Chougule MB. Nanocarrier mediated delivery of sirna/mirna in combination with chemotherapeutic agents for cancer therapy: current progress and advances. *Journal of Controlled Release*. 2014, 194, 238-256 DOI: 10.1016/j.jconrel.2014.09.001. PMID: 25204288 (IF- 7.26).
53. **Tekade RK**, Xu L, Hao G, Ramezani S, Silvers W, Christensen P, Sun X. A facile preparation of radioactive gold nanoplatfoms for potential theranostic agents of cancer. *Journal of Nuclear Medicine* 55 (supplement 1), 2014 1047-1047. (IF- 5.563).
54. **Tekade RK**, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Designing hybrid onconase nanocarriers for mesothelioma therapy: a taguchi orthogonal array and multivariate component driven analysis. *Molecular Pharmaceutics* 2014, 11, 3671-83. DOI: 10.1021/mp500403b. PMID: 25179221 (IF- 4.78).
55. Mody N, **Tekade RK**, Mehra NK, Chopdey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and plga nanoparticles: one platform assessment of drug delivery potential, *AAPS PharmSciTech*, 2014, 15, 388-99. DOI: 10.1208/s12249-014-0073-3. PMID: 24431104 (IF- 1.77).
56. **Tekade RK**, and Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: taguchi orthogonal array based design, *Biomed. Res. Int.*, 2013, 2013:712678, DOI: 10.1155/2013/712678. PMID: 24106715 (IF- 2.70).
57. Youngren SR, **Tekade RK**, Gustilo B, Hoffmann PR, Chougule MB. STAT-6 siRNA encapsulated nanocarriers: formulation, characterization, and ex-vivo proof of concept using adenocarcinomic cell line, *Biomed. Res. Int.*, 2013, 2013, DOI: 10.1155/2013/858946. PMID: 24191252 (IF- 2.70).
58. Thakur S, **Tekade RK**, Kesharwani P, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers, *J. Nanoparticle Research* 2013,15:1625 DOI:10.1007/s11051-013-1625-2 (IF- 2.27).

59. Dhakad RS, **Tekade RK**, Jain NK. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. *Current Drug Delivery*, 2013, 10, 10, 486-500 PMID: 23062180 (IF-2.24).
60. Dwivedi P, **Tekade RK**, Jain NK. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in alzheimer's disease, *Current Nanoscience*, 2013, 9, 46-55 DOI: 10.2174/1573413711309010010 (IF- 1.43).
61. **Tekade RK**, Emanuele AD, Elhissi A, Agrawal A, Jain A, Arafat BT, Jain NK. Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. *J. Biomedical Research*, 2013, 27, 394-405. DOI: 10.7555/JBR.27.20120123. PMID: 24086173. ISSN: 1674-8301
62. Maheshwari RGS, **Tekade RK**, Sharma PA, Gajanan D, Tyagi A, Patel RP, Jain DK. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment, *Saudi Pharm. J.* 2012, 20, 161–170 DOI: 10.1016/j.jsps.2011.10.001. PMID: 23960788 (IF- 2.233).
63. Chougule MB, **Tekade RK**, **Current Scene and prospective potentials of siRNA in cancer therapy**, *J Pharmacogenom Pharmacoproteomics* 2012, 3(6), e125.
64. Kayat J, Gajbhiye V, **Tekade RK**, Jain NK. Pulmonary toxicity by carbon nanotubes: A systematic report. *Nanomedicine*, 2011, 7, 40-49 DOI: 10.1016/j.nano.2010.06.008. PMID: 20620235. (IF- 5.98).
65. Kesharwani P, **Tekade RK**, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly (propylene imine) dendrimers: a comparison. *Nanomedicine* 2011, 7,295-304 DOI: 10.1016/j.nano.2010.10.010. PMID: 21070888 (IF- 5.98).
66. Kesharwani P, **Tekade RK**, Jain NK. Spectrophotometric estimation of paclitaxel. 2011, *Int. J. Adv. Pharm. Sci* 2 (1).
67. Kesharwani P, Gajbhiye V, **Tekade RK**, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. *Current Drug Targets* 2011, 12, 1478-97 PMID: 21443471 (IF: 3.029).
68. **Tekade RK**, Gajbhiye V, Rai K, Sharma M. Development of colorimetric method for determination of nitrazepam in tablets and bulks. *Int. J. Pharm. Pharma. Sci.* 2010, 1, 47-52. (IF- 0.49).
69. **Tekade RK**, Zhou Z, Jain NK, D'Emanuele A. A report on the use of a dendrimer carrier for a combined strategy of receptor up- regulation, enhanced cellular uptake and targeting for cancer therapy. *Proc. Int. Symp. Biol. Appl. Den.* 2010, P43
70. Agrawal A, **Tekade RK**, et al. Rapid RP-HPLC estimation of methotrexate in bulk, pharmaceutical preparation and in spiked plasma samples, *Journal of Pharmaceutical Research* 2010, 3, 6-7. (IF- 1.09).
71. Kurmi BD, Kayat J, Gajbhiye V, **Tekade RK**, Jain NK. Micro- and nanocarrier-mediated lung targeting. *Expert Opinion in Drug Delivery* 2010, 7, 781-794 DOI: 10.1517/17425247.2010.492212. PMID: 20560777. (IF- 4.11).
72. **Tekade RK**, Vijayarajkumar P, Jain NK, Dendrimers in oncology: An expanding horizon. *Chemical Reviews* (ACS) (2009), 109, 49-87 DOI: 10.1021/cr068212n. PMID: 19099452 (IF: 52.66).
73. Prajapati RN, **Tekade RK**, Gupta U, Gajbhiye V, Jain NK. Dendrimer-mediated solubilization, formulation development and *in vitro-in vivo* assessment of piroxicam. *Molecular Pharmaceutics* 2009, 6, 940–950. DOI: 10.1021/mp8002489. PMID: 19231841 (IF- 4.78).
74. Gajbhiye V, Vijayaraj Kumar P, **Tekade RK**, Jain NK. Dendrimer as therapeutic agents: A systematic review, *J. Pharm. Pharmacol.* 2009, 61, 989-1003. DOI: 10.1211/jpp/61.08.0002. PMID: 19703342 (IF- 2.363).
75. **Tekade RK**, Dutta T, Gajbhiye V, Jain NK, Exploring dendrimers towards dual-drug delivery: pH responsive simultaneous kinetics. *Journal of Microencapsulation*, 2009, 26, 287-296. DOI: 10.1080/02652040802312572. PMID: 18791906 (IF- 1.87).
76. Gajbhiye V, Vijayaraj Kumar P, **Tekade RK**, Jain NK, PEGylated PPI dendritic architectures for sustained delivery of H<sub>2</sub> receptor antagonist. *European J. Medicinal*

- Chemistry* 2009, 44, 1155-1166 DOI: 10.1016/j.ejmech.2008.06.012. PMID: 18760863. (IF- 3.43).
77. **Tekade RK**, Dutta T, Gajbhiye V, Jain N, Jain NK, Simultaneous spectrophotometric estimation of methotrexate and all trans retinoic acid in mixture. *Asian. Journal of Chemistry* 2009, 21, 5145-5150 (IF- 0.35).
78. **Tekade RK** and Jain NK, Six sigma: A growing quality management strategy, *Pharm. Rev.* 7, 2009, 68-76.
79. **Tekade RK**, Dutta T, Tyagi A, Bharti AC, Das BC, Jain NK. Surface engineered dendrimers for dual drug delivery: A receptor up-regulation and enhanced cancer targeting strategy. *Journal of Drug Targeting*, 2008, 16, 758-772. DOI: 10.1080/10611860802473154. PMID: 18985508 (IF- 2.72).
80. Gajbhiye V, Vijayaraj Kumar P, **Tekade RK**, Jain NK. Pharmaceutical and biomedical potential of PEGylated dendrimers. *Current Pharm. Design* 2007, 13, 415-429 10.2174/138161207780162999. (IF- 3.35).